- The trend backdrop is active with a 11-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
CTNM
NASDAQ
Week ended 11 Sep 2026
Weekly Investor Report
Contineum Therapeutics, Inc. Class A Common Stock · Healthcare · Biotechnology
Latest close
14.82 USD
-11.3%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 5.1% above the Trend Line and sits at 67.7% of its 52-week range. The latest completed week returned -11.3%, after a 4.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 45/100 conviction, while the latest news-sentiment score is 45/100. Near-term considerations: volume confirmation is below normal; earnings are due in 40d.
Setup score
56
out of 100
Latest Close
14.82 USD
11 Sep 2026
1W Return
-11.3%
latest completed week
4W Return
4.4%
short-term follow-through
12W Return
24.1%
quarterly tape
Trend Breadth
94.2%
49 of 52 weeks active
Volume Ratio
0.5x
vs 13-week average
- Next-week expectancy is negative at 44.48% based on similar historical setup states.
- The latest week was a sharp negative move.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-11.3%
Latest completed week; four-week move 4.4%.
Indicator stack
90/72
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 44.48%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
45/100 conviction; expected move 42.8%.
News sentiment
45/100
10 relevant articles in the latest sentiment read.
Event risk
40d
Next report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 5.1% above the Trend Line and sits at 67.7% of its 52-week range. The latest completed week returned -11.3%, after a 4.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
4 Sep
11 Sep
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7912-week average 0.65
12-week confirmation
Trend active11/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.79Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 4.4% over four weeks, 24.1% over 12 weeks, and 20.0% over one year. The current trend has remained active for 11 consecutive weeks.
Performance by holding period
Active trend streak11 weeks
Active weeks in one year49
Trend breadth94.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.91Latest activity-pressure read.
Pressure change70.7%Four-week change in activity pressure.
Leadership2.11Latest relative-leadership reading.
RS change169.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 11 Sep 2026
Financial statements through 30 Jun 2026
Field coverage 64%
Model confidence 64%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength23/100Blend of value, momentum, and quality. Underlying universe rank 78; rank 1 is best.
Value37/100Relative valuation strength. Underlying universe rank 64; rank 1 is best.
Quality35/100Profitability and accounting quality. Underlying universe rank 66; rank 1 is best.
Momentum37/100Medium-term price momentum. Underlying universe rank 64; rank 1 is best.
Growth37/100Revenue and earnings growth. Underlying universe rank 64; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -9.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -21.5% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -20.4% Net share repurchases relative to market value.
- Shareholder yield
- -20.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
CTNM shows volatility options pressure with a 45/100 conviction score, put-call volume ratio of 0.79, expected move of 42.8%, and Sharemaestro trend signal active.
Conviction45/100
Expected move42.8%
Put/call volume0.79
Insider activity-
No recent insider transactions are stored for this company.
News sentiment45/100
Weighted news tone is neutral across 10 relevant articles.
1 positive · 5 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings40dNext report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
Options expected move42.8%Nearest-chain priced movement where available.
52-week drawdown-16.7%Distance below the 52-week high.
13-week volatility9.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
20 Mar
17 Apr
15 May
12 Jun
10 Jul
7 Aug
11 Sep
Weeks higher13 of 2613 weeks finished lower.
Best week+21.1%Week of 21 Aug.
Worst week-14.8%Week of 5 Jun.
Latest week-11.3%Week of 11 Sep.
Shape of recent returns
Strong gains8
Modest gains5
Flat weeks0
Modest losses5
Sharp losses8
Recent vol9.2%13-week weekly-return volatility.
Base vol8.2%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew7.0% / -5.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average0.6%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD69.0%positive activity pressure
RS53.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-0.7%
Trend breadth76.0%
Trend76.0%active weekly trend signals
MD69.0%positive activity pressure
RS61.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape56/100
Trend, activity pressure, participation, and risk combine to a 56/100 tape read.
Indicator analysis81/100Latest 12-week confirmation: trend 11/12, activity pressure 10/12, relative leadership 11/12.
Activity pressure 0.79; No reversal markers Next-Week ExpectancyNegative 44.48%Next-week expectancy is negative with a 44.48% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors31/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 95; Small Cap Core rank 65 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options55/100CTNM shows volatility options pressure with a 45/100 conviction score, put-call volume ratio of 0.79, expected move of 42.8%, and Sharemaestro trend signal active.
Volatility · Volatility expansion watch · Expected move 42.8% Sentiment45/100Weighted news tone is neutral across 10 relevant articles.
Update: Contineum Therapeutics Shares Fall After Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint Insiders50/100No recent insider transaction evidence is stored.
Earnings40dNext report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 11 Sep 2026 | 14.82 USD | -11.3% | 14.10 USD | 12.51 USD | 0.91 | 2.11 | 1.1M | On |
| 4 Sep 2026 | 16.70 USD | -2.1% | 14.09 USD | 12.49 USD | 0.96 | 14.37 | 1.5M | On |
| 28 Aug 2026 | 17.05 USD | -0.8% | 14.03 USD | 12.46 USD | 0.92 | 17.53 | 2.3M | On |
| 21 Aug 2026 | 17.19 USD | 21.1% | 13.94 USD | 12.42 USD | 0.85 | 19.61 | 3.8M | On |
| 14 Aug 2026 | 14.19 USD | -5.7% | 13.80 USD | 12.38 USD | 0.54 | -3.03 | 3.6M | On |
| 7 Aug 2026 | 15.04 USD | -2.9% | 13.71 USD | 12.37 USD | 0.47 | 4.58 | 1.7M | On |
| 31 Jul 2026 | 15.49 USD | 10.2% | 13.52 USD | 12.35 USD | 0.47 | 14.25 | 1.3M | On |
| 24 Jul 2026 | 14.06 USD | -1.2% | 13.39 USD | 12.32 USD | 0.37 | 5.47 | 889.0K | On |
| 17 Jul 2026 | 14.23 USD | -6.3% | 13.33 USD | 12.31 USD | 0.42 | 6.13 | 1.1M | On |
| 10 Jul 2026 | 15.19 USD | 0.6% | 13.25 USD | 12.29 USD | 0.02 | 9.96 | 2.0M | On |
| 3 Jul 2026 | 15.10 USD | 6.4% | 13.13 USD | 12.26 USD | -0.57 | 12.87 | 1.8M | On |
| 26 Jun 2026 | 14.19 USD | 18.8% | 13.00 USD | 12.24 USD | -1.06 | 8.56 | 5.1M | Off |
| 19 Jun 2026 | 11.94 USD | 0.5% | 12.89 USD | 12.22 USD | -1.38 | -11.61 | 1.5M | Off |
| 12 Jun 2026 | 11.88 USD | 3.4% | 12.86 USD | 12.23 USD | -1.20 | -9.03 | 673.7K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.